Fluvastatin, a fully synthetic cholesterol-lowering agent, is a The parent drug is targeted to the liver and no active metabolites are present. Easy to read FDA package insert, drug facts, dosage and administration, and adverse effects for Lescol (fluvastatin). PACKAGE LEAFLET: INFORMATION FOR THE USER. Fluvastatin 20 mg and 40 mg Hard Capsules. (fluvastatin). Read all of this leaflet carefully before you.
|Published (Last):||2 December 2004|
|PDF File Size:||8.2 Mb|
|ePub File Size:||2.14 Mb|
|Price:||Free* [*Free Regsitration Required]|
Proposed Mechanisms of Myotoxicity The precise mechanisms underlying statin-associated myopathy are not well understood; however, theories do exist.
fluvastatin (LESCOL, LESCOL XL)
Lescol fluvastatin package insert. Limit use of 80 mg simvastatin. Pravachol pravastatin package insert. From there, properties of each statin must be taken into account to determine the best option for the individual pckage. If the symptoms do not resolve after approximately 2 weeks, the statin is likely not the cause and should be reinitiated at the original dose. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and packagr of cardiovascular disease.
Considerations in the Approach to Appropriate Statin Selection
Atorvastatin and fluastatin are also available generically in several combination products. Meta-analysis of placebo-controlled randomized controlled trials on the prevalence of statin intolerance. Additionally, the role of vitamin D has been somewhat controversial, as low levels are associated with both myalgia and poor muscle function.
Evolocumab and clinical outcomes in patients with cardiovascular disease.
Age is not a basis for exclusion from this criterion. Upon symptom resolution, a low dose of an alternative statin should be initiated and titrated to the maximum tolerated dose. Reference s National Institutes of Health, U.
The Use of Medicines in the United States: Cyclosporine and fluconazole are among the many agents that potentiate myopathy risk. Accessed September 21, Statins are generally well tolerated; however, discontinuation rates remain high. Mevacor lovastatin fluvaatatin insert. Available guidelines differ widely, but the one constant is that statins should be first-line therapy for primary and secondary prevention in nearly every patient.
However, if the symptoms resolve, a retrial of the same statin at the same or a lower dose should be undertaken. While paxkage patients may self-treat their symptoms with analgesics or pain relievers, oackage sudden unexplained muscle weakness or other symptoms should be conveyed to their physician.
Crestor rosuvastatin package insert. Please review the latest applicable package insert for additional information and possible updates. Common causes include old age, drug interactions, impaired renal or hepatic function, increased physical activity, and vitamin D deficiency.
Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study.
The highest predictors for myopathy were a previous history of unsert pain during lipid-lowering therapy, unexplained cramps, and an elevation in CK concentrations. References Crestor rosuvastatin package insert. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
When a statin is suspected as the cause of mild-to-moderate symptoms, temporary withdrawal is recommended. Inhibition of CoQ 10 or Ubiquinone: From tothe number of dispensed prescriptions for lipid regulators, which primarily include statins, has continuously increased from Decreases in serum ubiquinone do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans.
Adjustments lfuvastatin be made at intervals of weeks. Once patients are initiated on statin therapy, pharmacists have the opportunity to monitor patient adherence, treatment response, and medication safety, in addition to providing ongoing patient education on statin therapy and its adverse effects.
However, the risk-benefit ratio is unclear in patients with a very low risk of CVEs.